BNP Paribas Financial Markets Acquires New Shares in Stevanato Group S.p.A. (NYSE:STVN)

BNP Paribas Financial Markets acquired a new stake in Stevanato Group S.p.A. (NYSE:STVN - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 48,754 shares of the company's stock, valued at approximately $1,062,000.

A number of other institutional investors and hedge funds have also bought and sold shares of STVN. Van Berkom & Associates Inc. acquired a new stake in Stevanato Group in the fourth quarter valued at $39,000. Johnson Financial Group Inc. acquired a new stake in Stevanato Group in the fourth quarter valued at $41,000. Wells Fargo & Company MN increased its holdings in Stevanato Group by 680.3% in the fourth quarter. Wells Fargo & Company MN now owns 3,246 shares of the company's stock valued at $71,000 after purchasing an additional 2,830 shares during the period. PNC Financial Services Group Inc. increased its holdings in Stevanato Group by 1,457.6% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,654 shares of the company's stock valued at $123,000 after purchasing an additional 5,291 shares during the period. Finally, Tower Research Capital LLC TRC increased its holdings in Stevanato Group by 202.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 7,413 shares of the company's stock valued at $162,000 after purchasing an additional 4,965 shares during the period.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Stephens upgraded Stevanato Group to a "strong-buy" rating in a report on Monday, April 21st. UBS Group decreased their price target on Stevanato Group from $24.00 to $23.50 and set a "neutral" rating for the company in a report on Friday, March 7th. Finally, William Blair reiterated an "outperform" rating on shares of Stevanato Group in a report on Friday, March 7th. Two research analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of €25.70 ($29.20).

Stevanato Group Stock Down 1.6%

Shares of STVN stock traded down €0.37 ($0.42) on Monday, reaching €22.24 ($25.27). 159,500 shares of the company were exchanged, compared to its average volume of 343,538. The company has a market cap of $6.74 billion, a price-to-earnings ratio of 47.32, a PEG ratio of 7.18 and a beta of 0.51. The company has a 50-day moving average of €21.73 and a 200-day moving average of €21.32. The company has a debt-to-equity ratio of 0.22, a current ratio of 1.81 and a quick ratio of 1.21. Stevanato Group S.p.A. has a one year low of €16.56 ($18.82) and a one year high of €25.75 ($29.26).

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings results on Thursday, March 6th. The company reported €0.20 ($0.23) earnings per share for the quarter, meeting the consensus estimate of €0.20 ($0.23). Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business had revenue of €352.68 million for the quarter, compared to analysts' expectations of €346.26 million. Analysts anticipate that Stevanato Group S.p.A. will post 0.5 earnings per share for the current year.

Stevanato Group Increases Dividend

The firm also recently declared an annual dividend, which will be paid on Thursday, July 17th. Investors of record on Thursday, June 5th will be given a $0.0613 dividend. This is a boost from Stevanato Group's previous annual dividend of $0.05. The ex-dividend date of this dividend is Thursday, June 5th. This represents a yield of 0.3%. Stevanato Group's dividend payout ratio (DPR) is presently 11.76%.

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.